iTRAQ-Based Proteomics of Chronic Renal Failure Rats after FuShengong Decoction Treatment Reveals Haptoglobin and Alpha-1-Antitrypsin as Potential Biomarkers

Abstract EN

Background.

Chronic renal failure (CRF) has become a global health problem and bears a huge economic burden.

FuShengong Decoction (FSGD) as traditional Chinese medicine has multiple pharmacological effects.

Objectives.

To understand the underlying molecular mechanism and signaling pathway involved in the FSGD treatment of CRF and screen differentially expressed proteins in rats with CRF treated with FSGD.

Methods.

Thirty-three male Sprague-Dawley rats were randomly divided into control group, CRF group, and FSGD group.

Differentially expressed proteins were screened by iTRAQ coupled with nanoLC-MS/MS, and these identified proteins were later analyzed by GO, KEGG, and STRING.

Additionally, haptoglobin (HP) and alpha-1-antitrypsin (AAT) were finally verified by ELISA, Western blot, and real time PCR.

Results.

A total of 417 proteins were identified.

Nineteen differentially expressed proteins were identified in the FSGD group compared with the model group, of which 3 proteins were upregulated and 16 proteins were downregulated.

Cluster analysis indicated that inflammatory response was associated with these proteins and complement and coagulation cascade pathways were predominantly involved.

The validation methods further confirmed that the levels of HP and AAT were significantly increased.

Conclusions.

HP and AAT may be the important biomarkers in the pathogenesis of CRF and FSGD therapy.